Redwood Park Advisors’s Acrivon Therapeutics ACRV Stock Holding History

Redwood Park Advisors’s Portfolio ACRV Stock Details ACRV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$695	Hold	500	–	–	﹤0.01%	248
2025 Q4	$1.21K	Hold	500	–	–	﹤0.01%	235
2025 Q3	$905	Hold	500	–	–	﹤0.01%	254
2025 Q2	$595	Hold	500	–	–	﹤0.01%	272
2025 Q1	$1.01K	Hold	500	–	–	﹤0.01%	268
2024 Q4	$3.01K	Buy	+500	New	+$3.63K	﹤0.01%	228

Other funds holding ACRV

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

SCV

Sands Capital Ventures Arlington, Virginia $421M AUM 26.25% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

Jane Street New York $777B AUM 61.18% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Redwood Park Advisors's ACRV Position: Q1 2026 in Review

Redwood Park Advisors held its Acrivon Therapeutics (ACRV) position steady in Q1 2026 at 500 shares worth $695. The position accounts for ﹤0.01% of the portfolio, ranked #248.

Redwood Park Advisors first reported a position in ACRV in Q4 2024 and has held it in 6 quarters since. The position peaked at $3.01K in Q4 2024. 44 funds tracked by Wall St. Rank hold ACRV as of Q1 2026.

Redwood Park Advisors held 500 shares of Acrivon Therapeutics worth $695 as of Q1 2026.
Redwood Park Advisors left its Acrivon Therapeutics share count unchanged in Q1 2026.
Acrivon Therapeutics made up ﹤0.01% of Redwood Park Advisors's portfolio in Q1 2026, its #248 holding.
Redwood Park Advisors first reported a position in Acrivon Therapeutics in Q4 2024 and has held it in 6 quarters since.
Redwood Park Advisors's Acrivon Therapeutics position peaked at $3.01K in Q4 2024.
44 funds tracked by Wall St. Rank held Acrivon Therapeutics as of Q1 2026.

Based on Redwood Park Advisors's 13F filing for Q1 2026, filed 4 May 2026.